Lactate Dehydrogenase As A Prognostic Biomarker In Patients With Hormone Receptor-Positive Metastatic Breast Cancer Treated With Palbociclib: An Exploratory Cohort Study
EUROPEAN JOURNAL OF CANCER(2020)
Abstract
Background: Cyclin-dependent kinases (CDK) 4/6 inhibitors have recently reshaped the therapeutic scenario for hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC). Elevated serum lactate dehydrogenase (LDH) levels correlate with poor prognosis in various malignancies, including MBC. However, no data are available on LDH prognostic value in patients treated with CDK4/6 inhibitors. Henceforth, we explored whether plasmatic LDH could represent a prognostic biomarker in patients treated with endocrine therapy (ET) and the CDK4/6 inhibitor palbociclib.
MoreTranslated text
Key words
lactate dehydrogenase,breast cancer,prognostic biomarker,receptor-positive
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined